TP53 and neoplasm: In both the SIOP-PNET4 clinical trial and other independent cohorts, MYCN amplification within the SHH subgroup is strongly associated with TP53 mutation, LCA pathology and a very poor prognosis, whereas its detection in Group 4 tumours has no prognostic impact [28,38].